Cargando…
α-L-iduronidase therapy for mucopolysaccharidosis type I
More than 500 patients with mucopolysaccharidosis type IH (MPS IH; Hurler syndrome) have been treated with hematopoietic cell transplantation (HCT) throughout the world since the introduction of transplantation as therapy almost 30 years ago. More recently, the availability of recombinant α-L-iduron...
Autores principales: | Tolar, Jakub, Orchard, Paul J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727896/ https://www.ncbi.nlm.nih.gov/pubmed/19707455 |
Ejemplares similares
-
Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
por: Li, Ying, et al.
Publicado: (2022) -
Insights into Mucopolysaccharidosis I from the structure and action of α-L-Iduronidase
por: Bie, Haiying, et al.
Publicado: (2013) -
Three novel α-L-iduronidase mutations in 10 unrelated Chinese mucopolysaccharidosis type I families
por: Sun, Luning, et al.
Publicado: (2011) -
Mucopolysaccharidosis type I: molecular characteristics of two novel alpha-L-iduronidase mutations in Tunisian patients
por: Chkioua, Latifa, et al.
Publicado: (2011) -
Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice
por: Kida, Sachiho, et al.
Publicado: (2023)